Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline

Bibliography

• HALBREICH U, ENDICOTT J, SCHACHT S, NEE J: The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form.Acta Psychiatr. Scand. (1982) 65(1):46–65.
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG): Premenstrual Syndrome. Washington DC, ACOG (2000).
   Google Scholar
• AMERICAN PSYCHIATRICASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders Oh edit), American Psychiatric Press, Inc., Washington DC, USA (1994).
   Google Scholar
• STERNFELD B, SWINDLE R, CHAWLA A, LONG S, KENNEDY S: Severity of premenstrual symptoms in a health maintenance organization population. Obstet. Gynecol (2002) 99(6):1014–1024.
   PubMed Web of Science ®Google Scholar
• ROCA CA, SCHMIDT PJ,RUBINOW DR: A follow-up study of premenstrual syndrome. I Clin. Psychiatry (1999) 60(11):763–766.
   PubMedGoogle Scholar
• WITTCHEN HU, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psycho]. Med. (2002) 32(1):119–132.
   PubMed Web of Science ®Google Scholar
• •Documented that the prevalence of clinically significant dysphoric PMS is higher than the 5-8% strict PMDD. Women with the so-called 'subthreshold PMDD' do need treatment.
   Google Scholar
• HALBREICH U, BORENSTEIN J,PEARLSTEIN T, KAHN LS: The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology (2003) 28\(Suppl. 3):1–23.
   Google Scholar
• •The impact of dysphoric PMS/PMDD is well within the range of Axis I affective disorders. The burden of disease is more than is currently appreciated.
   Google Scholar
• CHAWLA A, SWINDLE R, LONG S, KENNEDY S, STERNFELD B: Premenstrual dysphoric disorder: is there an economic burden of illness? Med. Care. (2002) 40(11):1101–1112.
   Google Scholar
• COHEN LS, SOARES CN, OTTO MW et al.: Prevalence and predictors of premenstrual dysphoric disorder (PMDD)in older premenopausal women. The Harvard Study of Moods and Cycles. Affect. Disord. (2002) 70(2):125–132.
   PubMed Web of Science ®Google Scholar
• DEUSTER PA, ADERA T,SOUTH-PAUL J: Biological, social, and behavioral factors associated with premenstrual syndrome. Arch. Fam. Med. (1999) 8(2):122–128.
   PubMedGoogle Scholar
• ANGST J, SELLARO R,MERIKANGAS KR, ENDICOTT J:The epidemiology of perimenstrualpsychological symptoms.Acta Thychiatr. Scand. (2001) 104(2):110–116.
   Google Scholar
• SVEINDOTTIR H, BACKSTROM T: Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet. Gynecol Scand. (2000) 79(5):405–413.
   PubMedGoogle Scholar
• RIVERA-TOVAR AD, FRANK E: Late luteal phase dysphoric disorder in young women. Am. j Psychiatry (1990) 147(12):1634–1636.
   PubMed Web of Science ®Google Scholar
• GEHLERT S, HARTLAGE S: A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. .1. Psychosom. Obstet. Gynecol (1997) 18(1):36–44.
   Google Scholar
• CAMPBELL EM, PETERKIN D, O'GRADY K, SANSON-FISHER R: Premenstrual symptoms in general practice patients. Prevalence and treatment. .1. Reprod. Med. (1997) 42(10):637–646.
   Google Scholar
• JOHNSON SR, MCCHESNEY C, BEAN JA: Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J. Reprod. Med. (1988) 33(4):340–346.
   Google Scholar
• ANDERSCH B, WENDERSTAM C, HAHN L: Prevalence of premenstrual symptoms in a Swedish urban population. .1. Psychosom Obstet. Gynaecol (1986) 5:39.
   Google Scholar
• WOODS NF, MOST A, DERY GK: Prevalence of perimenstrual symptoms. Am. j Public Health (1982) 72(11):1257–1264.
   PubMed Web of Science ®Google Scholar
• RAMCHARAN S, LOVE EJ, FICK GH, GOLDFIEN A: The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J. Clin. Epidemiol (1992) 45(4):377–392.
   PubMed Web of Science ®Google Scholar
• HALBREICH U: Premenstrual dysphoric disorders, anxiety, and depressions:vulnerability traits or comorbidity [letter]. Arch. Gen. Psychiatry (1995) 52(7):606.
   PubMedGoogle Scholar
• HALBREICH U, ENDICOTT J: The relationship of dysphoric premenstrual changes to depressive disorders.Acta Psychiatr. Scand. (1985) 71(4):331–338.
   Google Scholar
• KASHIWAGI T, MCCLURE JN, WETZEL R: Premenstrual affective syndrome and psychiatric disorder. Dis. Nerv. Syst. (1976) 37:116–119.
   PubMedGoogle Scholar
• SCHUCKIT MA, DALY V, HERMAN G, HINEMAN S: Perimenstrual symptoms and depression in a university population. Dis. Nerv. Syst. (1975) 36:560–517.
   Google Scholar
• WENTZEL JN, REICH T,MCCLURE JM, WALD I: Premenstrual affective syndrome and affective disorder.Br. J. Psychiatry (1975) 127:219–221.
   PubMedGoogle Scholar
• HARRISON WM, ENDICOTT J, NEE J, GLICK H, RABKIN JG: Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics (1989) 30(4):405–411.
   PubMedGoogle Scholar
• PEARLSTEIN TB, FRANK E, RIVERA-TOVAR A et al.: Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J. Affect. Disord. (1990) 20:129–134.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, KAHN LS: Depression in Menopausal Women. In: Depression in Menopausal Women. Genazzani AR (Ed.), Parthenon Publishers, Lancaster, UK (2003).
   Google Scholar
• SUGAWARA M, TODA MA, SHIMA S et al.: Premenstrual mood changes and maternal mental health in pregnancy and the postpartum period. j Clin. Psycho]. (1997) 53(3):225–232.
   Google Scholar
• HALBREICH U: Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr. Scand. (1997) 95(3):169–176.
   PubMed Web of Science ®Google Scholar
• HALBREICH U: The etiology, biology, and evolving pathology (phila) of Premenstrual Syndromes. Psychoneuroendocrinology (2003) 28(Supp. 3):55–99.
   Google Scholar
• •Delineates the background for the diversified treatments for PMS/PMDD.
   Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, POLANSKY M: Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry (1999) 56(10):932–939.
   PubMed Web of Science ®Google Scholar
• •Not all antidepressants are equally effective for PMS/PMDD. Serotonergic agonists are more effective than noradreneline agonists.
   Google Scholar
• FREEMAN EW: Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.Carr. Psychiatry Rep. (2002) 4(6):435–440.
   Google Scholar
• MITWALLY ME KAHN LS, HALBREICH U: Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin. Pharmacother. (2002) 3(11):1577–1590.
   PubMedGoogle Scholar
• HALBREICH U: The pathophysiologic background for current treatments of premenstrual syndromes. Curr. Psychiatry Reports (2002) 4(6):429–434.
   PubMedGoogle Scholar
• PEARLSTEIN T: Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs (2002) 62(13):1869–1885.
   PubMed Web of Science ®Google Scholar
• COHEN L, MINER C, BROWN E et al: Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. (2002) 100(3):435–444.
   PubMed Web of Science ®Google Scholar
• MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo- controlled clinical trial. Clin. Ther. (2002) 24(3):417–433.
   PubMed Web of Science ®Google Scholar
• STEINER M, STEINBERG S, STEWART D et al.: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl. J. Med. (1995) 332(23):1529–1534.
   PubMedGoogle Scholar
• WOOD SH, MORTOLA JF, CHAN YF, MOOSSAZADEH F, YEN SS: Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet. Gynecol. (1992) 80(3 Pt 1):339–44.
   Google Scholar
• MENKES DB, TAGHAVI E, MASON PA, HOWARD RC: Fluoxetine's spectrum of action in premenstrual syndrome. Int. Clin. Psychopharmacol. (1993) 8(2):95–102.
   PubMed Web of Science ®Google Scholar
• SU TP, SCHMIDT PJ, DANACEAU MA et al.: Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology (1997) 16(5):346–356.
   PubMed Web of Science ®Google Scholar
• OZEREN S, CORAKCI A, YUCESOY I, MERCAN R, ERHAN G: Fluoxetine in the treatment of premenstrual syndrome. Eur. Obstet. Gynecol. Reprod. Biol. (1997) 73(2):167–170.
   PubMed Web of Science ®Google Scholar
• STONE AB, PEARLSTEIN TB,BROWN WA: Fluoxetine in the treatmentof late luteal phase dysphoric disorder. Clin. Psychiatry (199 1) 5 2 (7) :290–293.
   Google Scholar
• PEARLSTEIN TB, STONE AB,LUND SA et al: Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. (1997) 17(4):261–266.
   PubMedGoogle Scholar
• PEARLSTEIN T, YONKERS KA: Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin. Pharmacother. (2002) 3(7):979–991.
   PubMedGoogle Scholar
• YONKERS KA, HALBRIECH U, FREEMAN E et al: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. "AMA (1997) 278(12):983–988.
   PubMedGoogle Scholar
• •A large-scale, multi-centre study demonstrating the efficacy of continuous treatment with sertraline for PMDD.
   Google Scholar
• FREEMAN EW, RICKELS K,ARREDONDO F et al.: Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. Clin. Psychopharmacol. (1999) 19(1):3–8.
   Google Scholar
• •Luteal dosing with sertraline may be even more efficacious than continuous dosing.
   Google Scholar
• JERMAIN DM, PREECE CK, SYKES RL, KUEHL TJ, SULAK PJ: Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch. Fain. Med. (1999) 8(4):328–332.
   Google Scholar
• •Confirmatory pilot study.
   Google Scholar
• YOUNG SA, HURT PH, BENEDEK DM, HOWARD RS: Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial.Clin. Psychiatry (1998) 59(2):76–80.
   Google Scholar
• •An encouraging pilot study.
   Google Scholar
• HALBREICH U, SMOLLER JW:Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J. Clin. Psychiatry (1997) 58(9):399–402.
   PubMed Web of Science ®Google Scholar
• •First to demonstrate that women who respond well to continuous treatment with sertraline, also similarly respond to luteal intermittent dosing.
   Google Scholar
• HALBREICH U, BERGERON R, YONKERS KA et al: Efficacy ofintermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. (2002) 100(6):1219–1229.A large-scale, multi-centre study confirmingthe efficacy of luteal-phase dosing of sertraline as treatment for PMDD.
   Google Scholar
• ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology (1995) 12(2):167–176.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, WIKANDER I, ANDERSCH B, ERIKSSON E: A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur: Neuropsychopharmacol. (1997) 7(3):201–206.
   PubMed Web of Science ®Google Scholar
• YONKERS KA, GULLION C, WILLIAMS A, NOVAK K, RUSH AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. I Clin. Psychopharmacol. (1996) 16(1):3–8.
   Google Scholar
• WIKANDER I, SUNDBLAD C, ANDERSCH B et al.: Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Clin. Psychopharmacol. (1998) 18(5):390–398.
   Web of Science ®Google Scholar
• FREEMAN EW, JABARA S, SONDHEIMER SJ, AULETTO R: Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. I Womens Health Gend. Based Med. (2002) 11(5):459–464.
   PubMedGoogle Scholar
• ERIKSSON E, LISJO P, SUNDBLAD C et al.: Effect of clomipramine on premenstrual syndrome. Acta Psychiatr. Scand. (1990) 81(1):87–88.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand. (1992) 85(1):39–47.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, HEDBERG MA, ERIKSSON E: Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology (1993) 9(2):133–145.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, YONKERS KA et al.: Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol (2001) 98(5 Pt 1):737–744.
   Google Scholar
• LANDEN M, ERIKSSON 0, SUNDBLAD C et al: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) (2001) 155(3)292–298.
   Google Scholar
• MILLER MN, MILLER BE, CHINOUTH R, COYLE BR, BROWN GR: Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression. Depress. Anxiety (2002) 15(1):48–51.
   PubMedGoogle Scholar
• FREEMAN EW, RICKELS K,SONDHEIMER SJ et al.: Nefazodone in the treatment of premenstrual syndrome: a preliminary study. I Gin. Psychopharmacol (1994) 14(3):180–186.
   Google Scholar
• STEINBERG S, ANNABLE L,YOUNG SN, LIYANAGE N: A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol. Psychiatry (1999) 45(3):313–320.
   PubMed Web of Science ®Google Scholar
• HARRISON WM, ENDICOTT J, NEE J: Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch. Gen. Psychiatry (1990) 47(3):270–275.
   PubMed Web of Science ®Google Scholar
• EVANS SM, HANEY M, LEVIN FR, FOLTIN RW, FISCHMAN MW: Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology (1998) 19(6):499–516.
   PubMed Web of Science ®Google Scholar
• SMITH S, RINEHART JS,RUDDOCK VE, SCHIFF I: Treatment of premenstrual syndrome with alprazolam: results of a double- blind, placebo-controlled, randomized crossover clinical trial. Obstet. Gynecol (1987) 70(1):37–43.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, POLANSKY MP: A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome.JAMA (1995) 274(1):51–57.N.BERGER CP, PRESSER B: Alprazolam inthe treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet. Gynecol (1994) 84(3):379–85.
   Google Scholar
• SCHMIDT PJ, GROVER GN, RUBINOW DR: Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch. Gen. Psychiatry(1993) 50(6):467–473.
   PubMed Web of Science ®Google Scholar
• MUSE KN, CETEL NS,FUTTERMAN LA, YEN SC: The premenstrual syndrome. Effects of 'medical ovariectomy'. N Engl. Med. (1984) 311(21):1345–1349.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K, ALBERT J: Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study.Chit. Psychiatry (1993) 54(5):192–195.
   Google Scholar
• MEZROW G, SHOUPE D, SPICER D et al.: Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Feral. Stern. (1994) 62(5):932–937.
   PubMedGoogle Scholar
• LEATHER AT, STUDD JW,WATSON NR, HOLLAND EF: The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Gynecol Endocrinol (1999) 13(1):48–55.
   PubMed Web of Science ®Google Scholar
• WEST CP, HILLIER H: Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum. Reprod. (1994) 9(6):1058–1063.
   PubMedGoogle Scholar
• HUSSAIN SY, MASSIL JH, MATTA WH, SHAW RW, O'BRIEN PM: Buserelin in premenstrual syndrome. Gynecol Endocrinol (1992) 6(1):57–64.
   PubMed Web of Science ®Google Scholar
• SUNDSTROM I, NYBERG S, BIXO M, HAMMARBACK S, BACKSTROM T: Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol Scand. (1999) 78(10):891–899.
   PubMedGoogle Scholar
• HAMMARBACK S, BACKSTROM T: Induced anovulation as treatment of premenstrual tension syndrome: a double-blind crossover study with GnRH-agonists versus placebo. Acta Obtet. Gynecol Scand. (1988) 67:159–166.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K: Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. (1997) 33(2):303–309.
   PubMedGoogle Scholar
• BROWN CS, LING FW, ANDERSEN RN, FARMER RG, ARHEART KL: Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol (1994) 84(5):779–786.
   PubMed Web of Science ®Google Scholar
• SARNO AP Jr, MILLER EJ Jr,LUNDBLAD EG: Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet. Gynecol (1987) 70(1):33–36.
   PubMedGoogle Scholar
• HALBREICH U, ROJANSKY N, PALTER S: Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil. Stern. (1991) 56(6):1066–1069.
   PubMedGoogle Scholar
• O'BRIEN PM, ABUKHALIL IE: Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am. J. Obstet. Gynecol (1999) 180(1 Pt 1):18–23.
   Google Scholar
• PICKERSGILL A: GnRH agonists and add-back therapy: is there a perfect combination? Br: J. Obstet. Gynaecol (1998) 105(5):475–485.
   Google Scholar
• MIT WALLY ME GOTLIEB L,CASPER RF: Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.Menopause (2002) 9(4):236–241.
   PubMedGoogle Scholar
• STUDD J, LEATHER AT: The need for add-back with gonadotrophin-releasing hormone agonist therapy. Brit. J. Obstet. Gynaecol (1996) 103 (Suppl. 14):1–4.
   Google Scholar
• MORTOLAJF, GIRTON L, FISCHER U: Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. I Gin. Endocrinol Metab. (1991) 72(2):252A-252F.
   Google Scholar
• KOURI EM, HALBREICH U: State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull. (1997) 33(4):767–770.
   PubMedGoogle Scholar
• ASHBY CR Jr, CARR LA, COOK CL, STEPTOE MM, FRANKS DD: Alteration of platelet serotonergic mechanisms and monoamine wddase activity in premenstrual syndrome. Biol. Psychiatry (1988) 24(2):225–233.
   PubMedGoogle Scholar
• TAYLOR DL, MATHEW RJ, HO BT, WEINMAN ML: Serotonin levels and platelet uptake during premenstrualtension. Neuropsychobiology (1984) 12(1):16–18.
   PubMedGoogle Scholar
• ASHBY CR Jr, CARR LA, COOK CL, STEPTOE MM, FRANKS DD: Alteration of 5-HT uptake by plasma fractions in the premenstrual syndrome. Neural. Transm. Gen. Sect. (1990) 79(1-2):41–50.
   PubMedGoogle Scholar
• STEEGE JF, STOUT AL, KNIGHT DL, NEMEROFF CB: Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am." Obstet. Gynecol (1992) 167(1):168–172.
   Google Scholar
• RAPKIN AJ, EDELMUTH E,CHANG LC et al.: Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecolv (1987) 70(4):533–537.
   Google Scholar
• ROJANSKY N, HALBREICH U, ZANDER K, BARKAI A, GOLDSTEIN S: Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet. Invest. (1991) 31:146–152.
   PubMed Web of Science ®Google Scholar
• GOLD J, SEVERINO S: Premenstrual Dysphorias, Myths and Realities. American Psychiatric Association Press, Washington DC, USA (1994).
   Google Scholar
• BANCROFT J, COOK A, DAVIDSON D, BENNIE J, GOODWIN G: Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psycho]. Med. (1991) 21(2):305–312.
   PubMedGoogle Scholar
• SU TP, SCHMIDT PJ, DANACEAU M, MURPHY DL, RUBINOW DR: Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. Clin. Endocrinol Metab. (1997) 82(4):1220–1228.
   Google Scholar
• MELTZER HY, LOWRY MT: The serotonin hypothesis of depression. Raven Press, New York, USA (1987).
   Google Scholar
• DIMMOCK PW, WYATT KM,JONES PW, O'BRIEN PM: Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 356(9236):1131–1136.
   PubMed Web of Science ®Google Scholar
• VVYATT KM, DIMMOCK PW,O'BRIEN PMS: Selective serotonin reuptake inhibitors for premenstrual syndrome (Cochrane Review). In: Selective serotonin reuptake inhibitors for premenstrual syndrome (Cochrane Review)Oxford: Update Software (2003).
   Google Scholar
• STEINER M, KORZEKWA M, LAMONT J, WILKINS A: Intermittentfluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Buff (1997) 33(4):771–774.
   PubMedGoogle Scholar
• VVYATT K, DIMMOCK P, JONES P, OBHRAI M, O'BRIEN S: Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Brit. Med..). (2001) 323(7316):776–780.
   PubMedGoogle Scholar
• SCHMIDT PJ, NIEMAN LK,GROVER GN et al.: Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl. Med. (1991) 324(17):1174–1179.
   Google Scholar
• CHAN AF, MORTOLA JF, WOOD SH, YEN SS: Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet. Gynecol (1994) 84(6):1001–1005.
   PubMedGoogle Scholar
• MCRAE AL, BRADY KT: Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother. (2001) 2(5):883–892.
   PubMedGoogle Scholar
• HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Titer. (2000) 85(1):11–28.
   PubMed Web of Science ®Google Scholar
• REIMHERR FW, CHOUINARD G, COHN CK et al: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.j Clin. Psychiatry (1990) 51 (Suppl. B):18–27.
   Google Scholar
• KOCSIS JH, ZISOOK S, DAVIDSON J et al.: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am. Psychiatry (1997) 154(3):390–395.
   PubMedGoogle Scholar
• THASE ME, FAVA M, HALBREICH U et al.: A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch. Gen. Psychiatry (1996) 53(9):777–784.
   PubMed Web of Science ®Google Scholar
• BROWNE G, STEINER M, ROBERTS J et al.: Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. Affect. Disord. (2002) 68(2-3):317–330.
   PubMedGoogle Scholar
• Pfizer Inc.: Zoloft'" (Sertraline) Package Insert. Pfizer, Inc., USA (2002).
   Google Scholar
• RUDORFER MV, POTTER WZ: The role of metabolites of antidepressants and thetreatment of depression. CNS Drugs (1997) 7(4):273–312.
   PubMedGoogle Scholar
• DEVANE CL: Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. MM. Neurobiol (1999) 19(4):443–66.
   PubMedGoogle Scholar
• SCHWENK MH, VERGA MA, WAGNER JD: Hemodialyzability of sertraline. Clin. Nephrol (1995) 44(2):121–124.
   PubMedGoogle Scholar
• FINLEY PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. (1994) 28(12):1359–1369.
   PubMedGoogle Scholar
• FULLER RW: Basic advances in serotonin pharmacology. I Clin. Psychiatry (1992) 53(Suppl.):36–45.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, Revised edn) American Psychiatric Press, Inc., Washington DC, USA (1987).
   Google Scholar
• ENDICOTT J, HARRISON W: Daily rating of severity of problems form. New York: Department of Research Assessment and Training, New York State Psychiatric Institute (1990).
   Google Scholar
• HAMILTON M: A rating scale for depression. I Neurol Neurosurg. Psychiatry (1960) 23:56–62.
   PubMed Web of Science ®Google Scholar
• GUY W: ECDEU Assessment Manual for Psychopharmacology, Revised (Ef edn). US Department Of Health, Education and Welfare, Rockville, Maryland, USA (1976).
   Google Scholar
• VVEISSMAN MM, BOTHWELL S: Assessment of social adjustment by patient self-report. Arch. Gen. Psychiatry (1976) 33(9):1111–1115.
   PubMedGoogle Scholar
• ENDICOTT J, NEE J, HARRISON W, BLUMENTHAL R: Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharm. Bull. (1993) 29:321–326.
   PubMed Web of Science ®Google Scholar
• ENDICOTT J, NEE J, COHEN J, HALBREICH U: Premenstrual changes: Patterns and correlates of daily ratings. Affect. Disord. (1986) 10:127–135.
   PubMedGoogle Scholar
• MORTOLA JF, GIRTON L, BECK L, YEN SS: Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet. Gynecol (1990) 76(2):302–307.
   PubMed Web of Science ®Google Scholar
• TAMAM L, OZPOYRAZ N: Selective serotonin reuptake inhibitordiscontinuation syndrome: a review. Adv. Ther. (2002) 19(1):17–26.
   PubMedGoogle Scholar
• FAVA M, ROSENBAUM JF, HOOG S et al.: A comparison of symptoms following treatment interruption: evidence from a randomized double-blind trial with fluoxetine, sertraline, and paroxetine. Biol. Psychiatry (1998) 43 (Suppl. 8):69S.
   Google Scholar
• MICHELSON D, FAVA M, AMSTERDAM J et al.: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br. J. Psychiatry (2000) 176:363–368.
   PubMed Web of Science ®Google Scholar
• STAHL MM, LINDQUIST M, PETTERSSON M et al.: Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur.j Clin. Pharmacol (1997) 53(3-4):163–169.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ AC, ROTHBAUM BO: Review of sertraline in post-traumatic stress disorder. Expert Opin. Pharmacothec (2002) 3(10):1489–1499.
   PubMedGoogle Scholar
• LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Lit. Chit. Psychopharmacol (1996) 11 (Suppl. 5):31–61.
   Google Scholar
• NEMEROFF CB, DEVANE CL, POLLOCK BG: Newer antidepressants and the cytochrome P450 system. Am. Psychiatry (1996) 153(3):311–20.
   PubMed Web of Science ®Google Scholar
• MACQUEEN G, BORN L, STEINER M: The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev (2001) 7(1):1–24.
   PubMedGoogle Scholar
• HYMAN SE, ARANA GW,ROSENBAUM JF: Antidepressant Drugs In: Antidepressant Drugs. Little, Brown & Co., New York, NY, USA (1995):43–92.
   Google Scholar
• PERRY CM, BENFIELD P: Sertraline. An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs (1997) 7:480–500.
   Google Scholar
• OZDEMIR V, NARANJO CA, HERRMANN N et al.: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. Chit. Psychopharmacol (1998) 18(1):55–61.
   PubMedGoogle Scholar
• SPROULE BA, OTTON SV,CHEUNG SW et al.: CYP2D6 inhibition in patients treated with sertraline. Chit. Psychopharmacol (1997) 17(2):102–106.
   Google Scholar
• ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Chit. Psychopharmacol (1997) 17(4):284–291.
   PubMedGoogle Scholar
• KURTZ DL, BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ: The effect of sertraline on the pharmacokinetics of desipramine and imipramine.Chit. Pharmacol Ther. (1997) 62(2):145–156.
   Google Scholar
• PRESKORN SH, ALDERMAN J, CHUNG M et al: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Chit. Psychopharmacol (1994) 14(2):90–98.
   PubMed Web of Science ®Google Scholar
• ZUSSMAN BD, DAVIS CC, FOWLES SE et al.: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. Chit. Pharmacol (1995) 39:550P–551P
   Google Scholar
• SOLAI LK, MULSANT BH,POLLOCK BG et al: Effect of sertraline on plasma nortriptyline levels in depressed elderly.j Chit. Psychiatry (1997) 58(10):440–443.
   Google Scholar
• PRESKORN SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J. Psychopharmacol (1998) 12(3):S89–S97.
   Google Scholar
• GOODNICK PJ, GOLDSTEIN BJ: Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. Psychopharmacol (1998) 12(3):55–520.
   Google Scholar
• RAPEPORT WG, WILLIAMS SA, MUIRHEAD DC et al.: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Chit. Psychiatry (1996) 57\(Suppl. 1):20–23.
   Google Scholar
• PINNINTI NR, DE LEON J: Interaction of sertraline with clozapine. Chit. Psychopharmacol (1997) 17(2):119–120.
   PubMedGoogle Scholar
• CHONG SA, TAN CH, LEE HS: Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J. Chit. Psychopharmacol (1997) 17(1):68–69.
   PubMedGoogle Scholar
• PRESKORN SH, ALDERMAN J, GREENBLATT DJ, HORST WD: Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull. (1997) 33(4):659–665.
   PubMedGoogle Scholar
• CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR et al: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry (1996) 153(6):820–822.
   PubMed Web of Science ®Google Scholar
• HOEHNS JD, FOUTS MM, KELLY MW, TU KB: Sudden cardiac death with clozapine and sertraline combination. Ann. Pharmacothec (2001) 35(7-8):862–866.
   PubMed Web of Science ®Google Scholar
• HAMILTON SP, NUNES EV, JANAL M, WEBER L: The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am. Addict. (2000) 9(1):63–69.
   PubMedGoogle Scholar
• KAUFMAN KR, GERNER R: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7(2):163–165.
   PubMedGoogle Scholar
• HENDRICK V, ALTSHULER L: Management of major depression during pregnancy. Am. J. Psychiatry (2002) 159(10):1667–1673.
   PubMedGoogle Scholar
• HENDRICK V, SMITH LM, SURI R et al.: Birth outcomes after prenatal exposure to antidepressant medication. Am. Obstet. Gynecol (2003) 188(3):812–815.
   PubMed Web of Science ®Google Scholar
• SIMON GE, GOLDBERG D,TIEMENS BG, USTUN TB: Outcomes of recognized and unrecognized depression in an international primary care study.Gen. Hosp. Psychiatry (1999) 21(2):97–105.
   Google Scholar
• KULIN NA, PASTUSZAK A, SAGE SR et al.: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA (1998) 279(8):609–610.
   PubMed Web of Science ®Google Scholar
• WISNER KL, GELENBERG AJ, LEONARD H, ZARIN D, FRANK E: Pharmacologic treatment of depression during pregnancy. JAMA (1999) 282(13):1264–1269.
   PubMedGoogle Scholar
• STOWE ZN, HOSTETTER AL, OWENS MJ et al.: The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J. Chit. Psychiatry (2003) 64(1):73–80.
   PubMed Web of Science ®Google Scholar
• EPPERSON N, CZARKOWSKI KA, WARD-O'BRIEN D et al.: Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am. J. Psychiatry (2001) 158(10):1631–1637.
   Google Scholar
• STEINER M, MACDOUGALL M, BROWN E: The premenstrual symptomsscreening tool (PSST) for clinicians. Arch Women Ment. Health (2003) 6(3):203–209.
   PubMedGoogle Scholar
• PEARLSTEIN TB, HALBREICH U, BATZAR ED et al.: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. j. Clin. Psychiatry (2000) 61(2):101–109.
   PubMed Web of Science ®Google Scholar